Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter I Croucher

Showing results (11-20 of 104) with videos related to

Pageof 11
Sort By:
European Urology|December 4, 2014
Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease?Peter I Croucher, Belinda S Parker, Niall Corcoran, et al.
Current Opinion in Pharmacology|July 15, 2004
Evidence of a role for RANKL in the development of myeloma bone diseaseEvy De Leenheer, Gabrielle S Mueller, Karin Vanderkerken, et al.
Plos One|May 23, 2012
Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivoSrdjan Vitovski, Andrew D Chantry, Michelle A Lawson, et al.
Cancer Research|March 26, 2002
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cellsIngunn Holen, Peter I Croucher, Freddie C Hamdy, et al.
Biochemical and Biophysical Research Communications|October 22, 2008
Geranylgeranyl transferase type II inhibition prevents myeloma bone diseaseMichelle A Lawson, Les Coulton, Frank H Ebetino, et al.
Frontiers in Immunology|July 20, 2018
Single Cell RNA Sequencing of Rare Immune Cell PopulationsAkira Nguyen, Weng Hua Khoo, Imogen Moran, et al.
The Prostate|March 26, 2004
Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancerColby L Eaton, Jason M Wells, Ingunn Holen, et al.
The Journal of Endocrinology|August 19, 2016
Rapid phenotyping of knockout mice to identify genetic determinants of bone strengthBernard Freudenthal, John Logan, , et al.
Cancer Discovery|April 4, 2024
Chemotherapy and the Extra-Tumor Immune Microenvironment: EXTRA-TIMETri Giang Phan, Katherine N Weilbaecher, Rebecca Aft, et al.
Cancer Research|January 11, 2007
An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myelomaDeborah J Heath, Karin Vanderkerken, Xin Cheng, et al.
Pageof 11

Showing results (11-20 of 104) with videos related to

Sort By:
Pageof 11
European Urology|December 4, 2014
Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease?Peter I Croucher, Belinda S Parker, Niall Corcoran, et al.
Current Opinion in Pharmacology|July 15, 2004
Evidence of a role for RANKL in the development of myeloma bone diseaseEvy De Leenheer, Gabrielle S Mueller, Karin Vanderkerken, et al.
Plos One|May 23, 2012
Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivoSrdjan Vitovski, Andrew D Chantry, Michelle A Lawson, et al.
Cancer Research|March 26, 2002
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cellsIngunn Holen, Peter I Croucher, Freddie C Hamdy, et al.
Biochemical and Biophysical Research Communications|October 22, 2008
Geranylgeranyl transferase type II inhibition prevents myeloma bone diseaseMichelle A Lawson, Les Coulton, Frank H Ebetino, et al.
Frontiers in Immunology|July 20, 2018
Single Cell RNA Sequencing of Rare Immune Cell PopulationsAkira Nguyen, Weng Hua Khoo, Imogen Moran, et al.
The Prostate|March 26, 2004
Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancerColby L Eaton, Jason M Wells, Ingunn Holen, et al.
The Journal of Endocrinology|August 19, 2016
Rapid phenotyping of knockout mice to identify genetic determinants of bone strengthBernard Freudenthal, John Logan, , et al.
Cancer Discovery|April 4, 2024
Chemotherapy and the Extra-Tumor Immune Microenvironment: EXTRA-TIMETri Giang Phan, Katherine N Weilbaecher, Rebecca Aft, et al.
Cancer Research|January 11, 2007
An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myelomaDeborah J Heath, Karin Vanderkerken, Xin Cheng, et al.
Pageof 11